Revelation Biosciences Stock Price, News & Analysis

Revelation Biosciences (NASDAQ:REVB) announced groundbreaking results from its Phase 1b PRIME clinical study of Gemini in stage 3 and 4 chronic kidney disease (CKD) patients. The study met its primary safety endpoint and demonstrated significant efficacy in normalizing inflammatory response at the cellular level.

The trial enrolled 40 patients across 3 US clinics, divided into 5 cohorts. Key findings showed Gemini significantly reduced inflammation in patients with high background PBMC activity and corrected immunoparalysis typical to chronic disease. The drug was well-tolerated at the target dose, with mostly mild adverse events reported.

The company plans an End of Phase 1 meeting with the FDA later this year to discuss program advancement. The results suggest potential breakthrough applications for treating both acute and chronic inflammatory conditions.

Revelation Biosciences (NASDAQ:REVB) has issued a reminder for their upcoming webcast and conference call scheduled for September 10th at 8:30 am Eastern Time. The event will discuss top-line data from their PRIME Phase 1b clinical trial.

Participants can join via webcast or dial in using the toll-free number 888-506-0062 (US) or +1 973-528-0011 (International) with access code 289672. The company has made available both the original data announcement and the presentation materials on their website.

Revelation Biosciences (NASDAQ:REVB) announced positive top-line results from its Phase 1b PRIME clinical study of Gemini in stage 3 and 4 chronic kidney disease (CKD) patients. The study met its primary safety endpoint and demonstrated significant efficacy in normalizing inflammatory responses at the cellular level.

The study enrolled 40 patients across 3 US clinics, with 5 cohorts testing different dose levels. Notably, Gemini showed remarkable ability to reduce inflammation in patients with high background PBMC activity and correct immunoparalysis typical to chronic disease. The effects remained significant through 7 days after a single dose.

The treatment was well-tolerated at the target dose, with mostly mild adverse events. The company plans to discuss advancing the program with the FDA at an upcoming End of Phase 1 meeting.

Revelation Biosciences (NASDAQ: REVB) reported its financial results for Q2 2025, highlighting key operational and financial developments. The company completed patient dosing in the PRIME Phase 1b Clinical Study of Gemini in CKD patients and secured $4 million in gross proceeds from a public offering in May 2025.

Financial position shows $5.2 million in cash and cash equivalents as of June 30, 2025, down from $6.5 million at year-end 2024. The Q2 2025 net loss improved to $2.4 million ($(7.01) per share), compared to $8.4 million ($(246.27) per share) in Q2 2024. Current cash runway is expected to fund operations through December 2025.

Revelation Biosciences (NASDAQ:REVB) announced that its former chairman and shareholder, Dr. George Tidmarsh, has been appointed to head the FDA Center for Drug Evaluation and Research. Dr. Tidmarsh, who serves as an Adjunct Professor at Stanford University School of Medicine, has over three decades of biotech innovation experience and has successfully guided multiple medications through FDA approval.

Additionally, the company recently completed dosing in its PRIME Phase 1b clinical study of Gemini, investigating escalating doses administered intravenously in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).

Revelation Biosciences (NASDAQ: REVB) has completed patient dosing in its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study. The trial evaluated escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).

The study successfully enrolled 5 cohorts across 3 U.S. clinics. Multiple data sets are expected in Q3 2025, including safety parameters, hematologic changes, inflammatory response evaluation, and biomarker activity. The company plans to engage with the FDA to discuss future clinical development and approval pathways later in 2025.

Revelation Biosciences (NASDAQ: REVB) has announced a 1-for-3 reverse stock split effective July 7, 2025, following stockholder approval on June 23, 2025. The reverse split aims to increase the stock price to regain compliance with Nasdaq Capital Market's minimum bid listing requirements.

The company will maintain its trading symbol "REVB" with a new CUSIP number 76135L705. Proportionate adjustments will be made to conversion and exercise prices of warrants, restricted stock units, stock options, and shares under equity incentive plans. Additionally, REVB announced that enrollment for its PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete this month, with topline data anticipated shortly after.

Stockholders will see their shares automatically converted, with fractional shares rounded down. No action is required from registered stockholders or those holding shares through brokers.

Revelation Biosciences (NASDAQ: REVB) has closed its previously announced public offering, raising $4 million in gross proceeds. The offering included 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares at $1.10 per share. The warrants have a five-year expiration term from the initial exercise date. Roth Capital Partners served as the sole placement agent. The company plans to use the proceeds for product development, including completing their ongoing Phase 1b clinical study, manufacturing clinical drug supply, conducting preclinical work for multiple indications, developing other products, and funding working capital and general corporate purposes.

Revelation Biosciences (NASDAQ: REVB) has announced a $4 million public offering, pricing 3,640,000 shares of common stock at $1.10 per share. The offering includes warrants to purchase up to 14,560,000 additional shares, also at $1.10 per share, exercisable for 5 years after stockholder approval. Roth Capital Partners is serving as the sole placement agent. The proceeds will fund: (1) completion of ongoing Phase 1b clinical study, (2) clinical drug supply manufacturing, (3) preclinical work for multiple indications, (4) development of other products/therapies, and (5) working capital. The offering is expected to close around May 29, 2025, subject to customary conditions.